# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(3.32) per share which missed the analyst consensus estimate of $(3.11...
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end– ...
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulce...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programsPatent includes broad claims for "Gut...
– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in ...